Abattis Bioceuticals (Abattis Bioceuticals) EV-to-EBIT : 0.00 (As of Jun. 07, 2024)

Abattis Bioceuticals EV-to-EBIT Chart

Abattis Bioceuticals Annual Data
	Trend	Sep10	Sep11	Sep12	Sep13	Sep14	Sep15	Sep16	Sep17	Sep18	Sep19
EV-to-EBIT		Get a 7-Day Free Trial					-0.54	-3.04	-3.57	-0.86	-12.28

Abattis Bioceuticals Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
EV-to-EBIT	Get a 7-Day Free Trial															-0.86	-0.46	-0.57	-0.70	-12.28

Competitive Comparison of Abattis Bioceuticals's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Abattis Bioceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abattis Bioceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Abattis Bioceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Abattis Bioceuticals's EV-to-EBIT falls into.

Abattis Bioceuticals EV-to-EBIT Calculation

Abattis Bioceuticals's EV-to-EBIT for today is calculated as:

Abattis Bioceuticals's current Enterprise Value is $0.00 Mil.
Abattis Bioceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abattis Bioceuticals  (OTCPK:ATTBF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Abattis Bioceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2019 is calculated as:

Abattis Bioceuticals's Enterprise Value for the quarter that ended in Sep. 2019 was $8.62 Mil.
Abattis Bioceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abattis Bioceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Abattis Bioceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Abattis Bioceuticals (Abattis Bioceuticals) Business Description